Key result
Higher plasma CTRP9 linked to increased carotid IMT in T2D patients without chronic kidney disease.
Why the study?
Are plasma CTRP9 levels associated with carotid intima-media thickness in patients with type 2 diabetes?
Observational (n=419)
Are plasma CTRP9 levels associated with carotid intima-media thickness in patients with type 2 diabetes?
Plasma CTRP9 levels are independently associated with atherosclerosis progression (measured by carotid IMT) in patients with type 2 diabetes without chronic kidney disease.
Answers are grounded in this paper and cite their sources.
CTRP9 measurement should not yet inform T2D management; leaves open its role as atherosclerosis biomarker pending longitudinal studies.
Aim.C1q/tumor necrosis factor-related protein-9 (CTRP9), a paralog of adiponectin, is expressed in adipose tissue. CTRP9 exerts protective effects against obesity and atherosclerosis in rodents. We investigated the association between plasma CTRP9 levels and atherosclerosis in patients with type 2 diabetes.Methods.We included 419 patients with type 2 diabetes, 161 of whom had chronic kidney disease (CKD). Fasting plasma CTRP9 and total adiponectin levels were measured with enzyme-linked immunosorbent assay. The intima-media thickness (IMT) of the common carotid artery was measured with ultrasonography.Results. Plasma CTRP9 levels were higher in the CKD group than in the non-CKD group. Plasma CTRP9 levels were positively correlated with carotid IMT in the non-CKD group. Multivariate analyses revealed that plasma CTRP9 levels were positively associated with carotid IMT in the non-CKD group, independent of age, sex, body mass index, adiponectin, and other cardiovascular risk factors. However, plasma CTRP9 levels were not associated with carotid IMT in the CKD group.Conclusion.Plasma CTRP9 levels are associated with atherosclerosis in diabetic patients without CKD, independently of obesity, adiponectin, and traditional cardiovascular risk factors. This study indicates a potential role of CTRP9 in atherosclerosis progression in human type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Asada et al. (2016) conducted an observational in Type 2 diabetes (n=419). Plasma CTRP9 levels was evaluated on Carotid intima-media thickness (IMT). Plasma CTRP9 levels were positively associated with carotid intima-media thickness in type 2 diabetes patients without chronic kidney disease, independent of traditional cardiovascular risk factors.
Synapse has enriched 10 related papers. Consider them for comparative context: